Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone302-498-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.88 billion
Profitability
Miscellaneous
Employees1,367
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Tuesday, July, 30th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.37. The biopharmaceutical company earned $529.93 million during the quarter, compared to analysts' expectations of $498.57 million. Incyte had a net margin of 15.25% and a return on equity of 17.10%. The firm's revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.63 earnings per share. View Incyte's Earnings History.
When is Incyte's next earnings date?
How can I listen to Incyte's earnings call?
Incyte will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for INCY?
23 equities research analysts have issued twelve-month price targets for Incyte's stock. Their forecasts range from $74.00 to $111.00. On average, they expect Incyte's stock price to reach $92.48 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price. View Analyst Price Targets for Incyte.
What is the consensus analysts' recommendation for Incyte?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.
What are Wall Street analysts saying about Incyte stock?
Here are some recent quotes from research analysts about Incyte stock:
- 1. According to Zacks Investment Research, "Incyte’s lead drug, Jakafi continues to maintain momentum for the company, as the underlying patient demand for the drug remains strong for both MF and PV. Incyte is working to expand the drug’s label into additional indications which should further boost sales. The FDA approval of Olumiant 2 mg, for which the company received a milestone payment from Lilly, is a positive. Shares have outperformed the industry in the past six months. However, pipeline setbacks continue to be a concern. The FDA’s extension of the review period of the sNDA for the label expansion of Jakafi to treat acute GVHD was disappointing. Earlier, Incyte suffered a setback with the failure of the phase III ECHO-301 study, evaluating epacadostat in combination with Keytruda." (4/29/2019)
- 2. Raymond James analysts commented, "We are reiterating our Strong Buy rating for Incyte. This morning, the company announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for Jakafi for the treatment of patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The priority review grants a 6 month review period by the FDA, resulting in a PDUFA date of approximately March 25, 2019. Based on positive data from the REACH1 study, we remain confident regarding Incyte’s expansion into the steroid refractory GVHD market, which we estimate to be a ~$500 million market opportunity in the U.S." (10/25/2018)
- 3. Cantor Fitzgerald analysts commented, ". We are increasing our price target to $74 from $73 and reiterating our Neutral rating on INCY. At the ongoing ESMO, INCY provided updated Fight-202 results in cholangiocarcinoma, which looked superior to the previously disclosed initial data. Additionally, in a late-breaker presentation, Novartis (NVS, Not Covered) reported Phase II results from its MET inhibitor capmatinib in MET-mutated advanced non-small cell lung cancer (NSCLC) patients. Note that NVS received worldwide rights for capmatinib from INCY. NVS reported promising response rate data that compare favorably to earlier reported results from any MET inhibitors." (10/21/2018)
Has Incyte been receiving favorable news coverage?
News headlines about INCY stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Incyte earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Incyte.
Are investors shorting Incyte?
Incyte saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,990,000 shares, an increase of 25.4% from the August 30th total of 3,980,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 4.3 days. Approximately 2.3% of the company's stock are sold short. View Incyte's Current Options Chain.
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE) and Eloxx Pharmaceuticals (ELOX).
What other stocks do shareholders of Incyte own?
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
- Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
- Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)
Who are Incyte's major shareholders?
Incyte's stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.24%), Country Trust Bank (0.17%), Gulf International Bank UK Ltd (0.02%), Pacer Advisors Inc. (0.02%), State of Alaska Department of Revenue (0.01%) and Tributary Capital Management LLC (0.01%). Company insiders that own Incyte stock include Barry P Flannelly, David W Gryska, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar and Yao Wenqing. View Institutional Ownership Trends for Incyte.
Which institutional investors are selling Incyte stock?
INCY stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Advantage Investment Management LLC, Crossmark Global Holdings Inc., Gulf International Bank UK Ltd, Landsberg Bennett & Dubbaneh LLC and Tributary Capital Management LLC. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein and Yao Wenqing. View Insider Buying and Selling for Incyte.
Which institutional investors are buying Incyte stock?
INCY stock was acquired by a variety of institutional investors in the last quarter, including Polianta Ltd, Pacer Advisors Inc., Country Trust Bank, Fox Run Management L.L.C., First Hawaiian Bank and State of Alaska Department of Revenue. Company insiders that have bought Incyte stock in the last two years include Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $78.52.
How big of a company is Incyte?
Incyte has a market capitalization of $16.89 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe.View Additional Information About Incyte.
What is Incyte's official website?
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (NASDAQ INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
